“I worked with Michelle for over 2 years at Aptive. During that time she was a “Data Scientist Specialist” and really served as the Head of Data Science and a subject matter expert for healthcare evaluation. Michelle has tremendous leadership skills, she helped build and maintain a Data Excellence Community of Practice that extended company-wide and included all the data-geeks (like myself) and provided us a space to continue learning and developing our skills from each other's experience and expertise. I worked closely with Michelle to design and execute analyses to evaluate the effectiveness, patient satisfaction, cost-effectiveness for 10+ national, mental healthcare programs at Veterans Affairs - resulting in 2 Congressional reports and 3 peer-reviewed journal articles. Michelle really brought together the strengths of epidemiology and data science to elevate our team’s work. She is friendly and approachable, and she can have effective conversations with technical leads as well as senior leadership. Michelle would be a tremendous asset to any company and I would enthusiastically endorse her for any role.”
Michelle Winkler, PhD, MPH
Pittsburgh, Pennsylvania, United States
410 followers
406 connections
Activity
-
Day 31 of being laid off. It's hard to believe it's been a month since I was let go from my last position. Every day has been a new challenge, but…
Day 31 of being laid off. It's hard to believe it's been a month since I was let go from my last position. Every day has been a new challenge, but…
Liked by Michelle Winkler, PhD, MPH
-
I granted myself 4 hours of Volunteer Time Off (VTO) yesterday to attend the Virginia Symphony Orchestra’s Young People’s Concert with my son and his…
I granted myself 4 hours of Volunteer Time Off (VTO) yesterday to attend the Virginia Symphony Orchestra’s Young People’s Concert with my son and his…
Liked by Michelle Winkler, PhD, MPH
-
I recently lost my job due to DOGE's massive cuts on government contracts. The uncertainty of losing a job is excruciating, but losing a job that you…
I recently lost my job due to DOGE's massive cuts on government contracts. The uncertainty of losing a job is excruciating, but losing a job that you…
Liked by Michelle Winkler, PhD, MPH
Experience
Education
Publications
-
Clinic type and patient characteristics affecting time to resolution after an abnormal cancer-screening exam.
Cancer Epidemiology, Biomarkers & Prevention
Research shows that multilevel factors influence healthcare delivery and patient outcomes. The study goal was to examine how clinic type [academic medical center (AMC) or federally qualified health center (FQHC)] and patient characteristics influence time to resolution (TTR) among individuals with an abnormal cancer-screening test enrolled in a patient navigation (PN) intervention. Data were obtained from the Ohio Patient Navigation Research Project, a group-randomized trial of 862 patients…
Research shows that multilevel factors influence healthcare delivery and patient outcomes. The study goal was to examine how clinic type [academic medical center (AMC) or federally qualified health center (FQHC)] and patient characteristics influence time to resolution (TTR) among individuals with an abnormal cancer-screening test enrolled in a patient navigation (PN) intervention. Data were obtained from the Ohio Patient Navigation Research Project, a group-randomized trial of 862 patients from 18 clinics in Columbus, Ohio. TTR of patient after an abnormal breast, cervical, or colorectal screening test and the clinics' patient and provider characteristics were obtained. Descriptive statistics and Cox shared frailty proportional hazards regression models of TTR were used. The mean patient age was 44.8 years and 71% of patients were white. In models adjusted for study arm, FQHC patients had a 39% lower rate of resolution than AMC patients (P = 0.004). Patient factors of having a college education, private insurance, higher income, and being older were significantly associated with lower TTR. After adjustment for factors that substantially affected the effect of clinic type (patient insurance status, education level, and age), clinic type was not significantly associated with TTR. These results suggest that TTR among individuals participating in PN programs are influenced by multiple socioeconomic patient-level factors rather than clinic type. Consequently, PN interventions should be tailored to address socioeconomic status factors that influence TTR. These results provide clues regarding where to target PN interventions and the importance of recognizing predictors of TTR according to clinic type.
Other authors -
-
Prognosis and conditional disease-free survival among ovarian cancer patients.
Journal of Clinical Oncology
Traditional disease-free survival (DFS) does not reflect changes in prognosis over time. Conditional DFS accounts for elapsed time since achieving remission and may provide more relevant prognostic information for patients and clinicians. This study aimed to estimate conditional DFS among patients with ovarian cancer and to evaluate the impact of patient characteristics. Patients were recruited as part of the Hormones and Ovarian Cancer Prediction case-control study and were included in the…
Traditional disease-free survival (DFS) does not reflect changes in prognosis over time. Conditional DFS accounts for elapsed time since achieving remission and may provide more relevant prognostic information for patients and clinicians. This study aimed to estimate conditional DFS among patients with ovarian cancer and to evaluate the impact of patient characteristics. Patients were recruited as part of the Hormones and Ovarian Cancer Prediction case-control study and were included in the current study if they had achieved remission after a diagnosis of cancer of the ovary, fallopian tube, or peritoneum (N = 404). Demographic and lifestyle information was collected at enrollment; disease, treatment, and outcome information was abstracted from medical records. DFS was calculated using the Kaplan-Meier method. Conditional DFS estimates were computed using cumulative DFS estimates. Median DFS was 2.54 years (range, 0.03-9.96 years) and 3-year DFS was 48.2%. The probability of surviving an additional 3 years without recurrence, conditioned on having already survived 1, 2, 3, 4, and 5 years after remission, was 63.8%, 80.5%, 90.4%, 97.0%, and 97.7%, respectively. Initial differences in 3-year DFS at time of remission between age, stage, histology, and grade groups decreased over time. DFS estimates for patients with ovarian cancer improved dramatically over time, in particular among those with poorer initial prognoses. Conditional DFS is a more relevant measure of prognosis for patients with ovarian cancer who have already achieved a period of remission, and time elapsed since remission should be taken into account when making follow-up care decisions.
Other authors -
Use of Fertility Drugs and Risk of Ovarian Cancer
Current Opinion in Obstetrics and Gynecology
The purpose of this review is to highlight recent research and insights into the relationship between fertility drug use and ovarian cancer risk.Results from two large case-control studies provided further evidence that fertility drug use does not significantly contribute to risk of ovarian cancer among the majority of women when adjusting for known confounding factors. However, questions regarding the effect on certain subgroups, including long-term fertility drug users, women who remain…
The purpose of this review is to highlight recent research and insights into the relationship between fertility drug use and ovarian cancer risk.Results from two large case-control studies provided further evidence that fertility drug use does not significantly contribute to risk of ovarian cancer among the majority of women when adjusting for known confounding factors. However, questions regarding the effect on certain subgroups, including long-term fertility drug users, women who remain nulligravid after fertility treatment, women with BRCA1 or BRCA2 mutations and borderline ovarian tumours, still remain. In addition, it may currently just be too early to determine whether there is an association between fertility drug use and ovarian cancer risk given that many of the exposed women are only now beginning to reach the ovarian cancer age range.
Whether use of fertility drugs increases the risk of ovarian cancer is an important question that requires further investigation, in particular given the large number of women utilizing fertility treatments. Fortunately, results from recent studies have been mainly reassuring. Large well designed studies with sufficient follow-up time are needed to further evaluate the effects of fertility treatments within subgroups defined by patient and tumour characteristics.Other authors -
-
Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case-control study.
Cancer Epidemiology, Biomarkers & Prevention
Previous studies examining associations between use of fertility drugs and ovarian cancer risk have provided conflicting results. We used data from a large case-control study to determine whether fertility drug use significantly impacts ovarian cancer risk when taking into account parity, gravidity, and cause of infertility.Data from the Hormones and Ovarian Cancer Prediction (HOPE) study were used (902 cases, 1,802 controls). Medical and reproductive histories were collected via in-person…
Previous studies examining associations between use of fertility drugs and ovarian cancer risk have provided conflicting results. We used data from a large case-control study to determine whether fertility drug use significantly impacts ovarian cancer risk when taking into account parity, gravidity, and cause of infertility.Data from the Hormones and Ovarian Cancer Prediction (HOPE) study were used (902 cases, 1,802 controls). Medical and reproductive histories were collected via in-person interviews. Logistic regression was used to calculate ORs and 95% confidence intervals (CI). Models were adjusted for age, race, education, age at menarche, parity, oral contraceptive use, breastfeeding, talc use, tubal ligation, and family history of breast/ovarian cancer. Ever use of fertility drugs was not significantly associated with ovarian cancer within the total HOPE population (OR, 0.93; 95% CI, 0.65-1.35) or among women who reported seeking medical attention for infertility (OR, 0.87; 95% CI, 0.54-1.40). We did observe a statistically significant increased risk of ovarian cancer for ever use of fertility drugs among women who, despite seeking medical attention for problems getting pregnant, remained nulligravid (OR, 3.13; 95% CI, 1.01-9.67).These results provide further evidence that fertility drug use does not significantly contribute to ovarian cancer risk among the majority of women; however, women who despite infertility evaluation and fertility drug use remain nulligravid, may have an elevated risk for ovarian cancer. Our results suggest that fertility drug use does not significantly contribute to overall risk of ovarian cancer when adjusting for known confounding factors.
Other authors -
Recommendations received
1 person has recommended Michelle
Join now to viewMore activity by Michelle
-
A very happy Birthday to our President and CEO, Dr. Kristin Washington, PsyD, PMP 🧁✨🙌🏾
A very happy Birthday to our President and CEO, Dr. Kristin Washington, PsyD, PMP 🧁✨🙌🏾
Liked by Michelle Winkler, PhD, MPH
-
In reshaping federal health organizations for enhanced efficiency and effectiveness, I reflect on the invaluable teachings of the late Dr. Jerod Loeb…
In reshaping federal health organizations for enhanced efficiency and effectiveness, I reflect on the invaluable teachings of the late Dr. Jerod Loeb…
Liked by Michelle Winkler, PhD, MPH
-
I keep spreading the word that your network is your net worth. Not just because I like rhyming, but post-military my network made the difference in…
I keep spreading the word that your network is your net worth. Not just because I like rhyming, but post-military my network made the difference in…
Liked by Michelle Winkler, PhD, MPH
-
💜 Happy International Women’s Day! 💜 At W2 Consulting, we recognize and celebrate the strength, resilience, and leadership of women—not just…
💜 Happy International Women’s Day! 💜 At W2 Consulting, we recognize and celebrate the strength, resilience, and leadership of women—not just…
Liked by Michelle Winkler, PhD, MPH
-
Thrilled to share that I have joined the amazing team at Pariva Heath. Living in a home that supports a Neurodivergent Child while now working for an…
Thrilled to share that I have joined the amazing team at Pariva Heath. Living in a home that supports a Neurodivergent Child while now working for an…
Liked by Michelle Winkler, PhD, MPH
-
The VA’s decision to accelerate its EHR modernization is a crucial step toward improving care for veterans, but the timing also raises concerns…
The VA’s decision to accelerate its EHR modernization is a crucial step toward improving care for veterans, but the timing also raises concerns…
Liked by Michelle Winkler, PhD, MPH
-
Today’s insight on day one at HIMSS Global Health Conference & Exhibition 2025! The Five Rights of AI for Healthcare: A Framework for Responsible…
Today’s insight on day one at HIMSS Global Health Conference & Exhibition 2025! The Five Rights of AI for Healthcare: A Framework for Responsible…
Liked by Michelle Winkler, PhD, MPH
-
I am so very grateful to the loving support from those who have reached out to say I am sorry you lost your job so abruptly, without warning. That…
I am so very grateful to the loving support from those who have reached out to say I am sorry you lost your job so abruptly, without warning. That…
Liked by Michelle Winkler, PhD, MPH
-
Over 20 years working closely with federal employees in health agencies, with a few exceptions, I objectively and definitively know several things…
Over 20 years working closely with federal employees in health agencies, with a few exceptions, I objectively and definitively know several things…
Liked by Michelle Winkler, PhD, MPH
-
For my fellow #GovCon folks who have been laid off: Tell your story. To your family. To your friends. When you go out in your communities. When you…
For my fellow #GovCon folks who have been laid off: Tell your story. To your family. To your friends. When you go out in your communities. When you…
Liked by Michelle Winkler, PhD, MPH
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More